ATE295176T1 - Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen - Google Patents

Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen

Info

Publication number
ATE295176T1
ATE295176T1 AT98924800T AT98924800T ATE295176T1 AT E295176 T1 ATE295176 T1 AT E295176T1 AT 98924800 T AT98924800 T AT 98924800T AT 98924800 T AT98924800 T AT 98924800T AT E295176 T1 ATE295176 T1 AT E295176T1
Authority
AT
Austria
Prior art keywords
autistic
treatment
differential diagnosis
autistic syndrome
secretin
Prior art date
Application number
AT98924800T
Other languages
English (en)
Inventor
Karoly Horvath
Victoria Beck
Original Assignee
Repligen Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repligen Corp filed Critical Repligen Corp
Application granted granted Critical
Publication of ATE295176T1 publication Critical patent/ATE295176T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/121—Ketones acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A61K36/484—Glycyrrhiza (licorice)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2235—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/645—Secretins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/38—Pediatrics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
AT98924800T 1997-05-19 1998-05-19 Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen ATE295176T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US4704997P 1997-05-19 1997-05-19
PCT/US1998/010224 WO1998052593A1 (en) 1997-05-19 1998-05-19 Method for assisting in differential diagnosis and treatment of autistic syndromes

Publications (1)

Publication Number Publication Date
ATE295176T1 true ATE295176T1 (de) 2005-05-15

Family

ID=21946797

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98924800T ATE295176T1 (de) 1997-05-19 1998-05-19 Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen

Country Status (8)

Country Link
US (3) US6020310A (de)
EP (1) EP1019072B1 (de)
JP (1) JP2002501616A (de)
AT (1) ATE295176T1 (de)
AU (1) AU748147B2 (de)
CA (1) CA2290556A1 (de)
DE (1) DE69830185D1 (de)
WO (1) WO1998052593A1 (de)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6150321A (en) * 1996-12-12 2000-11-21 Colgate-Palmolive Co. Chemical linker compositions
US6197746B1 (en) 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
US6020310A (en) 1997-05-19 2000-02-01 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
US6020314A (en) * 1998-08-11 2000-02-01 Milkhaus Laboratory, Inc. Methods for treatment of neurological disorders
DE19902773A1 (de) * 1999-01-25 2000-07-27 Sertuerner Arzneimittel Gmbh Anticholestatische Wirksamkeit von Luteolin
US6552000B2 (en) * 1999-02-08 2003-04-22 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating autism
AU4989700A (en) * 1999-05-06 2000-11-21 Children's Hospital Of Los Angeles Autism gene
DE19953339A1 (de) * 1999-11-05 2001-05-17 Goldham Pharma Gmbh Secretinfragmente
US6599882B1 (en) 1999-11-05 2003-07-29 Joseph A. Rogoff Secretin and secretin pharmaceuticals for treating lactose intolerance
US6534063B1 (en) 1999-12-17 2003-03-18 Joan M. Fallon Methods for treating pervasive development disorders
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US6365593B2 (en) * 2000-04-12 2002-04-02 Repligen Corporation Methylxanthines in the diagnosis and treatment of autistic disorder
GB0016441D0 (en) * 2000-07-04 2000-08-23 Pharmagene Lab Limited Therapeutic method
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
WO2002014537A2 (en) * 2000-08-14 2002-02-21 Fallon Joan M Methods for diagnosing and treating dysautonomia and other dysautonomic conditions
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
WO2003028668A2 (en) * 2001-10-04 2003-04-10 Protein Therapeutics, Inc. Gammaglobulin treatment of immune disorders
US8100844B2 (en) * 2002-04-25 2012-01-24 Ultraflex Systems, Inc. Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint
WO2004100899A2 (en) * 2003-05-13 2004-11-25 The Mclean Hospital Corporation Use of secretin in treatments of disorders associated with the amygdala
JP2005082490A (ja) * 2003-09-04 2005-03-31 Kirin Brewery Co Ltd 脳機能改善剤
US7381698B2 (en) * 2003-12-12 2008-06-03 Chirhoclin, Inc. Methods for treatment of acute pancreatitis
US7947285B2 (en) * 2003-12-12 2011-05-24 Fein Seymour H Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
WO2007067714A2 (en) * 2005-12-08 2007-06-14 The Mclean Hospital Corporation Treatment of sequelae of psychiatric disorders
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US20090324730A1 (en) * 2008-06-26 2009-12-31 Fallon Joan M Methods and compositions for the treatment of symptoms of complex regional pain syndrome
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (de) 2008-07-01 2019-06-12 Curemark, Llc Verfahren und zusammensetzungen zur behandlung von symptomen von neurologischen und geistesstörungen
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) * 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
EP2443259A4 (de) * 2009-06-16 2012-10-10 Univ Columbia Biomarker für autismus und verwendungen davon
US9050276B2 (en) 2009-06-16 2015-06-09 The Trustees Of Columbia University In The City Of New York Autism-associated biomarkers and uses thereof
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
CA2778181C (en) 2009-10-26 2024-05-28 Thomas Julius Borody Therapy for enteric infections
RU2460466C2 (ru) * 2010-10-28 2012-09-10 Федеральное государственное учреждение "Российский научный центр восстановительной медицины и курортологии Федерального агентства по здравоохранению и социальному развитию РФ" (ФГУ "РНЦВМиК Росздрава") Способ определения уровня нервно-психического развития ребенка первого года жизни
US8529547B2 (en) * 2011-04-05 2013-09-10 Olympus Corporation Method of collecting specimen and method of diagnosing subject to detect upper digestive system disease
CN103460045B (zh) 2011-04-05 2016-01-20 奥林巴斯株式会社 胰脏检查方法及胰脏检查试剂盒
US8586384B2 (en) * 2011-04-05 2013-11-19 Olympus Corporation Method of collecting duodenal specimen to detect upper digestive system disease without using pancreatic or bile stimulant
CN106310242B (zh) 2011-04-21 2020-02-28 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
JP6042985B2 (ja) * 2013-07-02 2016-12-14 オリンパス株式会社 膵疾患マーカー検出用十二指腸液試料の決定方法、及び膵疾患マーカーの検出方法
WO2018191233A1 (en) 2017-04-10 2018-10-18 Curemark, Llc Compositions for treating addiction
US11464789B2 (en) 2018-08-03 2022-10-11 Enterin, Inc. Aminosterol compositions and methods of using the same for treating schizophrenia
CN109182577B (zh) * 2018-09-25 2022-03-15 深圳市英马诺生物科技有限公司 自闭症生物标志物及其应用
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3833722A (en) 1971-03-16 1974-09-03 D Graybill Method for controlling allergies
JPS5029005B2 (de) * 1972-05-08 1975-09-19
US3987014A (en) * 1974-01-10 1976-10-19 Becton, Dickinson And Company Secretin intermediates and derivatives
DE2615229C2 (de) * 1976-04-08 1984-05-24 Hoechst Ag, 6230 Frankfurt Verfahren zur Herstellung und Reinigung von Sekretin
US4086220A (en) * 1976-08-09 1978-04-25 G. D. Searle & Co. Fragments of secretin
EP0021184B1 (de) * 1979-06-13 1984-02-08 Hoechst Aktiengesellschaft Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin
NZ196349A (en) 1980-03-07 1984-08-24 Interx Research Corp Enhancement of absorption rate of orally administered polar bioactive agents
JPS58140024A (ja) * 1982-02-15 1983-08-19 Eisai Co Ltd セクレチンの精製方法
DE3328793A1 (de) * 1983-08-10 1985-02-28 Hoechst Ag, 6230 Frankfurt Herstellung von sekretin
SE454513B (sv) * 1985-03-11 1988-05-09 Kabigen Ab Humant sekretin samt kompositioner innehallande detta
JPS61277618A (ja) * 1985-06-04 1986-12-08 Suntory Ltd 自閉症治療剤
US5008251A (en) * 1986-03-27 1991-04-16 The Regents Of The University Of California Method of treating autism
US4994467A (en) * 1989-05-31 1991-02-19 Zimmerman Andrew W Treating autism and other developmental disorders in children with NMDA receptor antagonists
US5094837A (en) * 1990-01-22 1992-03-10 Wayne State University Method for use of magnetic resonance imaging to image pancreas using secretin
US5225407A (en) * 1990-02-22 1993-07-06 Glaxo Group Limited 5-HT3 receptor antagonists for the treatment of autism
US5380872A (en) 1992-07-14 1995-01-10 Glaxo Inc. Modulators of cholecystokinin
EP0681491B1 (de) 1993-01-29 2000-12-13 Aradigm Corporation Intrapulmonares hormonabgabesystem
US5527825A (en) * 1994-04-06 1996-06-18 University Of Arkansas Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase
GB9417524D0 (en) 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
US5686311A (en) * 1995-06-23 1997-11-11 The Children's Mercy Hospital Diagnosis of autism and treatment therefor
US6197746B1 (en) * 1998-05-19 2001-03-06 Repligen Corporation Method of using secretin for treating autism
US6020310A (en) * 1997-05-19 2000-02-01 Repligen Corporation Method for assisting in differential diagnosis and treatment of autistic syndromes
FR2767830B1 (fr) 1997-08-26 2000-02-04 Sod Conseils Rech Applic Oligonucleotides permettant l'identification de precurseurs d'hormones polypeptidiques amidees

Also Published As

Publication number Publication date
AU748147B2 (en) 2002-05-30
AU7688598A (en) 1998-12-11
US6020310A (en) 2000-02-01
US6498143B1 (en) 2002-12-24
DE69830185D1 (de) 2005-06-16
JP2002501616A (ja) 2002-01-15
EP1019072B1 (de) 2005-05-11
EP1019072A4 (de) 2002-06-19
US7091182B2 (en) 2006-08-15
EP1019072A1 (de) 2000-07-19
CA2290556A1 (en) 1998-11-26
WO1998052593A1 (en) 1998-11-26
US20040146495A1 (en) 2004-07-29

Similar Documents

Publication Publication Date Title
ATE295176T1 (de) Verfahren zur unterstützung der differentialdiagnostik und behandlung von autistischen syndromen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
DE69230112D1 (de) Fortschrittliches arzneistoffabgabesystem und verfahren zur behandlung von psychiatrischen, neurologischen und anderen erkrankungen mit carbamazepin
SE8501050D0 (sv) Biologically active fragments of human antihemophilic factor and method for preparation thereof
DE69930739D1 (de) Transdermale verwendung von sekretin zur behandlung von autismus
DE69333321D1 (de) Verwendung eines Consensus-Interferons zur Reduzierung der Nebeneffekte in der Interferon Behandlung von viralen Hepatiten.
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
ATE66374T1 (de) Zubereitungen und verfahren zur behandlung von blutungsstoerungen.
EA200401070A1 (ru) Способы лечения сосудистых заболеваний
EP0376251A3 (en) An anticoagulant substance obtained from urine
DK505584D0 (da) Administrationssaet og farmaceutiske praeparater til anvendelse dertil
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
KR950031063A (ko) 프라바스타틴을 이용하여 관상 동맥 아테롬성 동맥경화증의 진행 속도를 감소시키는 방법
KR950703004A (ko) 콜라겐-자극 혈소판 응집의 억제(inhibitor of collagen-stimulated platelet aggregation)
FI953565A7 (fi) Uusi antikoagulanttikofaktoriaktiivisuus
ATE44156T1 (de) Kovalent gebundener heparin-antithrombin iiikomplex, verfahren zu dessen herstellung und seine verwendung zur behandlung von thrombusembolie.
DE69625682D1 (de) Verfahren zur behandlung von entzündungen und zusammensetzungen dafür
DE69822810D1 (de) Somatostatin und somatostatin agoniste zur behandlung der insulinsunempfindlichkeit und syndrome x
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
DE69733321D1 (de) Olanzapine zur behandlung von drogenmissbrauch
DE3650368D1 (de) Verwendung von Depogen zur Behandlung von eingeschränktem Blutkreislauf.
RU93000004A (ru) Вещество для лечения подкожной фибрасаркомы и способ его получения
RU2043103C1 (ru) Средство, уменьшающее внешнесекреторную недостаточность поджелудочной железы при хроническом панкреатите
NO961180L (no) Transdermal anordning inneholdende (E)-2-(p-fluorfenetyl)-3-fluorallylamin for behandling av Alzheimers sykdom
DK563886A (da) Terapeutisk komposition

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties